Medical Marijuana, Inc. Investment AXIM(R) Biotechnologies, Inc. Publishes Product Pipeline Chart for Pharma Clinical Trials Program

Cannabinoid Innovator s Product Pipeline Highlights Timelines of Its Intellectual Property (IP) Protected Cannabinoid-Based Products from Pre-Clinical to NDA for Multiple Indications SAN DIEGO, CA MJNA, (Marketwired November 03, 2016) Medical Marijuana, Inc. (OTC: MJNA) today announced that its investment AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has published a product pipeline chart on its website that highlights the timelines from pre-clinical to a new drug application (NDA) for its numerous
http://bit.ly/2ei36e2